Dr. Sandler Discusses Docetaxel With Hormonal and Radiation Therapy in Patients With Prostate Cancer

September 28, 2015
Howard M. Sandler, MD, MS, FASTRO

Special Reports, Prostate Cancer (Issue 1), Volume 1, Issue 1

Howard M. Sandler, MD, MS, FASTRO, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.

Howard M. Sandler, MD, MS, FASTRO, Chair, Radiation Oncology, Ronald H. Bloom Family Chair, Cancer Therapeutics, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.

Sandler said that he and his colleagues enrolled men with very high-risk prostate cancer. Half of the patients had gleason 9 or 10, and most of the rest had gleason 8, with a very high PSA. This was a subset of patients with aggressive disease, so they represent the group that is most likely to benefit, adds Sandler.

Toxicities with the addition of docetaxel were expected. An increase in mild to moderate hematological toxicity was observed.